NYSE · Healthcare
CRYO CELL INTERNATIONAL INC (CCEL)
As-reported financials and recent SEC filings for CRYO CELL INTERNATIONAL INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$31.6M
Net income
$-2.4M
Net margin
-7.7%
Diluted EPS
$-0.30
ROE
13.1%
P/E (TTM)
—
Market cap
—
Debt / equity
-0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M | $28.9M |
| Gross profit | $24.2M | $24.0M | $23.0M | $21.5M | $19.9M |
| Operating income | $482,394 | $3.5M | $-12.3M | $4.0M | $4.0M |
| Net income | $-2.4M | $402,095 | $-9.5M | $2.8M | $2.1M |
| Diluted EPS | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.25 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-05-29
View on EDGAR →8-K2026-05-08
View on EDGAR →10-Q2026-04-14
View on EDGAR →SCHEDULE 13D2026-03-25
View on EDGAR →8-K2026-03-12
View on EDGAR →10-K2026-02-27
View on EDGAR →42026-01-09
View on EDGAR →42026-01-09
View on EDGAR →Largest Healthcare peers
Go deeper on CCEL
Search CRYO CELL INTERNATIONAL INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.